İnsan Proteomu: Protein İzoformları, Oluşum Mekanizmaları ve Hastalıklarla İlişkisi
Özet
İnsan Genom Projesi sonrasında insan proteomunun, alternatif uçbirleştirme, alternatif transkripsiyon başlama bölgesi, alternatif poliadenilasyon ve alternatif translasyon başlama bölgesi seçimi gibi mekanizmalarla 20.000 civarındaki genden çok daha fazla sayıda protein izoformu üreterek geniş bir çeşitlilik kazandığı anlaşılmıştır. Bu protein izoformları hücresel düzeyde farklı işlev, dağılım ve ifadelere sahip olup organizmanın fizyolojik dengesini korumada kritik roller üstlenmektedir. İnsan Proteom Projesi (HPP) de bu karmaşık yapıyı haritalamayı ve hastalıkların moleküler patolojisini aydınlatmayı amaçlamaktadır. Araştırmalar, bu izoform oluşum mekanizmalarında meydana gelen hataların veya düzensizliklerin doğrudan insan sağlığını bozarak birçok ciddi patoloji ile bağlantılı olduğunu göstermiştir. Örneğin alternatif uçbirleştirme kusurları Alzheimer, Konjenital Miyastenik Sendrom, Duchenne Kas Distrofisi ve Miyotonik Distrofide önemli rol oynarken, kritik kontrol noktalarındaki mutasyonlar ve intron tutma olayları çeşitli kanser türlerinin gelişimini tetiklemektedir. Benzer şekilde alternatif transkripsiyon ve poliadenilasyon bölgelerindeki varyasyonlar kalp yetmezliği, Frajil X Sendromu ve hematolojik hastalıklar ile ilişkiliyken, alternatif translasyon başlama hataları ve dokuya özgül plektin izoformlarındaki mutasyonlar kas distrofisi ve deri hastalıklarına yol açmaktadır.
Following the comprehensive analysis of the Human Genome Project, it has been realized that the human proteome achieves extensive diversity, producing significantly more protein isoforms than the approximately 20,000 protein-coding genes through mechanisms such as alternative splicing, alternative transcription start site selection, alternative polyadenylation, and alternative translation initiation site selection. These protein isoforms possess distinct functions, cellular distributions, and expressions, playing critical roles in maintaining physiological balance. The Human Proteome Project (HPP) actively aims to map this complex architecture to provide a foundation for understanding the molecular pathology of diseases. Studies demonstrate that errors or dysregulations in these isoform generation factors are heavily linked to various human pathologies. For instance, alternative splicing defects play crucial roles in Alzheimer's disease, Congenital Myasthenic Syndrome, Duchenne Muscular Dystrophy, and Myotonic Dystrophy, while mutations at critical checkpoints and intron retention events trigger cancer development. Similarly, variations in alternative transcription and polyadenylation site selections are associated with heart failure, Fragile X Syndrome, and susceptibility to malignancies, whereas alternative translation initiation errors and mutations in tissue-specific plectin isoforms lead to muscular dystrophies and skin disorders.
Referanslar
Pertea M, Shumate A, Pertea, G, et al. CHESS: A new human gene catalog curated from thousands of large-scale RNA sequencing experiments reveals extensive transcriptional noise. Genome Biology. 2018; 19, 208.
Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genetics. 2008; 40(12), 1413–1415.
Hedman AC, Smith JM, Sacks DB. The biology of IQGAP proteins: beyond the cytoskeleton. EMBO Reports. 2015; 16(4), 427–446.
HUPO. Human Proteome Project 2022 (31/01/2022 tarihinde https://hupo.org/human-proteome-project adresinden ulaşılmıştır).
Reixachs-Solé M, Eyras E. Uncovering the impacts of alternative splicing on the proteome with current omics techniques. WIREs RNA. 2022; e1707. Doi: 10.1002/wrna.1707.
Chow LT, Gelinas RE, Broker TR, et al. An amazing sequence arrangement at the 50 ends of adenovirus 2 messenger RNA. Cell. 1977; 12, 1–8.
Gilbert W.Why genes in pieces? Nature. 1978; 271, 501.
Barbosa-Morais NL, Irimia M, Pan Q, et al. The evolutionary landscape of alternative splicing in vertebrate species. Science (New York, N.Y.). 2012; 338(6114), 1587–1593.
Marquez Y, Brown JW, Simpson C, et al. Transcriptome survey reveals increased complexity of the alternative splicing landscape in Arabidopsis. Genome Research. 2012; 22(6), 1184–1195.
Cui Y, Cai M, Stanley HE. Comparative analysis and classification of cassette exons and constitutive exons. Biomed Research International. 2017; 2017. https://doi.org/10.1155/2017/7323508.
Zhan X, Yan C, Zhang X, et al. Structures of the human pre-catalytic spliceosome and its precursor spliceosome. Cell Research. 2018; 28, 1129–1140.
Thanaraj TA, Clark F. Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Research. 2001; 29, 2581–2593.
Iwata H, Gotoh O. Comparative analysis of information contents relevant to recognition of introns in many species. BMC Genomics. 2011; 12, 45.
Lander ES, Linton LM, Birren B, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001; 412, 565–566.
Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456, 470–476.
Fu XD, Ares M. Context-dependent control of alternative splicing by RNA-binding proteins. Nature Reviews Genetics. 2014; 15, 689–701.
Lovci MT, Ghanem D, Marr H, et al. Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nature Structural & Molecular Biology. 2013; 20, 1434–1442.
Bradley T, Cook ME, Blanchette M. SR proteins control a complex network of RNA-processing events. RNA. 2015; 21, 75–92.
Erkelenz S, Mueller WF, Evans MS, et al. Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. RNA. 2013; 19, 96–102.
Yee BA, Pratt GA, Graveley BR, et al. RBP-maps enables robust generation of splicing regulatory maps. RNA. 2019; 25, 193–204.
Sandelin A, Carninci P, Lenhard B. Mammalian RNA polymerase II core promoters: insights from genome-wide studies. Nature Reviews Genetics. 2007; 8(6), 424–36.
Forrest AR, Kawaji H, Rehli M, et al. A promoter-level mammalian expression atlas. Nature. 2014; 507(7493), 462–470.
Kimura K, Wakamatsu A, Suzuki Y, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters ofhuman genes. Genome Research. 2006; 16(1), 55–65.
de Klerk E, t Hoen PA. Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. Trends Genetics. 2015; 31(3), 128–139.
Davuluri RV, Suzuki Y, Sugano S, et al. The functional consequences of alternative promoter use in mammalian genomes. Trends in Genetics. 2008; 24, 167–177.
Tasic B, Nabholz CE, Baldwin KK, et al. Promoter choice determines splice site selection in Protocadherin α and γ pre-mRNA splicing. Molecular Cell, 2002, 10, 21–33.
Tamarkin-Ben-Harush A, Vasseur JJ, Debart F, et al. Cap-proximal nucleotides via differential eIF4E binding and alternative promoter usage mediate translational response to energy stress. eLife. 2017; 6, e21907.
Edmonds M, Vaughan MH Jr, Nakazato H. Polyadenylic acid sequences in the heterogeneous nuclear RNA and rapidly-labeled polyribosomal RNA of HeLa cells: possible evidence for a precursor relationship. Proceedings of National Academy of Sciences USA. 1971; 68, 1336–1340.
Darnell J E, Wall R, Tushinski RJ. An adenylic acid-rich sequence in messenger RNA of HeLa cells and its possible relationship to reiterated sites in DNA. Proceedings of National Academy of Sciences USA. 1971; 68, 1321–1325.
Tian B, Hu J, Zhang H. & Lutz CS. A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Research. 2005; 33, 201–212.
Yuan F, Hankey W, Wagner EJ. Alternative polyadenylation of mRNA and its role in cancer. Genes & Diseases. 2021; 8, 61e72.
Gruber AJ, Zavolan M. Alternative cleavage and polyadenylation in health and disease. Nature Reviews Genetics, 2019 Oct; 20(10), 599-614. Doi: 10.1038/s41576-019-0145-z.
Kishor A, Fritz SE, Haque N, et al. Activation and inhibition of nonsense-mediated mRNA decay control the abundance of alternative polyadenylation products. Nucleic Acids Research. 2020; 48, 7468–7482.
Moqtaderi Z, Geisberg JV, & Struhl K. Extensive structural differences of closely related 30 mRNA isoforms: Links to Pab1 binding and mRNA stability. Molecular Cell. 2018, 72, 849–861, e6.
Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nature Reviews. Molecular Cell Biology. 2016; 18, 18–30. https://pubmed.ncbi.nlm.nih.gov/27677860/.
Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene. 2005; 361, 13–37.
Kochetov AV. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. BioEssays. 2008; 30, 683–691.
Iacono M, Mignone F, Pesole G. uAUG and uORFs in human and rodent 5′untranslated mRNAs. Gene. 2005; 349, 97–105. Doi: 10.1016/j.gene.2004.11.041.
Calvo SE, Pagliarini DJ, Mootha VK. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proceedings of National Academy of Sciences USA. 2009; 106, 7507–7512.
Lee DSM, Park J, Kromer A, et al. Disrupting upstream translation in mRNAs is associated with human disease. Nature Communications. 2021; 12(1), 1515. Doi: 10.1038/s41467-021-21812-1.
Du X, Wang J, Zhu H, et al., Second Cistron in CACNA1A Gene Encodes a Transcription Factor Mediating Cerebellar Development and SCA6. Cell. 2013; 154(1), 118–133.
Tumbarello DA, Brown MC, Hetey SE et al., Regulation of paxillin family members during epithelial-mesenchymal transformation: a putative role for paxillin delta. Journal of Cell Science. 2005; 118(20), 4849–4863.
Barber RC. The genetics of Alzheimer's disease. Scientifica (Cairo). 2012; 2012, 246210. Doi: 10.6064/2012/246210.
Zilka N, Filipcik P, Koson P, et al. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Letters. 2006; 580, 3582–3588.
Zhang Z, Song M, Liu X, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nature Medicine. 2014; 20, 1254–1262.
Garcia‑Escudero V, Ruiz‑Gabarre D, Gargini R, et al. A new non‑aggregative splicing isoform of human Tau is decreased in Alzheimer’s disease. Acta Neuropathologica. 2021; 142, 159–177.
Masters CL, Bateman R, Blennow K, et al. Alzheimer’s disease. Nature Reviews Disease Primers. 2015; 1, 15056. https://doi.org/10.1038/nrdp.2015.56
Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013; 152, 1237–1251.
Marques-Coelho D, da Cruz Carvalho Iohan L, Melo de Farias AR, et al. Differential transcript usage unravels gene expression alterations in Alzheimer's disease human brains. NPJ Aging and Mechanisms of Disease. 2021; 7(1), 2. Doi: 10.1038/s41514-020-00052-5.
Allen M, Carrasquillo MM, Funk C, et al. Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases. Scientific Data. 2016; 3, 160089.
De Jager PL, Ma Y, McCabe C, et al. Data descriptor: a multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research. Scientific Data. 2018, 5, 180142. https://doi.org/10.1038/sdata.2018.142.
Wang M, BeckmanN ND, Roussos P, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer’s disease. Scientific Data. 2018; 5, 1–16.
Raj B, Blencowe BJ. Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. Neuron. 2015; 87, 14–27.
Alam S, Suzuki H, Tsukahara T. Alternative splicing regulation of APP exon 7 by RBFox proteins. Neurochemistry International. 2014; 78, 7–17.
Palace J, Beeson D. The congenital myasthenic syndromes. Journal of Neuroimmunology. 2008; 201-202, 2–5.
Rahman MA, Azuma Y, Nasrin F, et al. SRSF1 and hnRNP H antagonistically regulate splicing of COLQ exon 16 in a congenital myasthenic syndrome. Scientific Reports. 2015; 5, 13208.
Ohno K, Engel AG. Congenital myasthenic syndromes:gene mutations. Neuromuscular Disorders. 2003; 13, 854–857.
Verdile V, Guizzo G, Ferrante G, et al. RNA Targeting in Inherited Neuromuscular Disorders: Novel Therapeutic Strategies to Counteract Mis-Splicing. Cells. 2021; 10, 2850. https://doi.org/ 10.3390/cells10112850.
An J, Xie Z, Jia F, et al. Quantitative coordination evaluation for screening children with Duchenne muscular dystrophy. Chaos. 2020; 30(2), 023116.
Hoffman EP. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. Acta Myologica. 2020; 39, 179–186.
Den Dunnen JT, Grootscholten PM, Bakker E, et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. American Journal of Human Genetics. 1989; 45, 835–847.
Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD Global Database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations. Human Mutation. 2015; 36, 395–402.
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurology. 2003; 2, 731–740.
Malhotra SB, Hart KA, Klamut HJ, et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science. 1988; 242, 755–759.
Dwianingsih EK, Malueka RG, Nishida A, et al. A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy. Journal of Human Genetics. 2014; 59, 423–429.
Deburgrave N, Daoud F, Llense S, et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Human Mutation. 2007; 28, 183–195.
Sibley CR, Blazquez L, Ule J. Lessons from non-canonical splicing. Nature Reviews Genetics. 2016; 17, 407–421.
Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000; 289, 1769–1773.
Fardaei M, Larkin K, Brook JD, et al. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Research. 2001; 29, 2766–2771.
Mosthaf L, Grako K, Dull TJ, et al. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO Journal. 1990; 9, 2409–2413.
Vogt B, Carrascosa JM, Ermel B, et al. The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. Biochemical and Biophysical Research Communications. 1991; 177, 1013–1018.
Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insülin resistance in myotonic dystrophy. Nature Genetics. 2001; 29, 40–47.
Rau F, Lainé J, Ramanoudjame L, et al. Abnormal splicing switch of DMD’s penultimate exon compromises muscle fibre maintenance in myotonic dystrophy. Nature Communications. 2015; 6, 7205.
Dolatshad H, Pellagatti A, Fernandez-Mercado M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015; 29(5), 1092–1103.
Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood, American Society of Hematology. 2012; 119 (15), 3578–3584.
Je EM, Yoo NJ, Kim YJ, et al. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. International Journal of Cancer. 2013; 133(1), 260–265.
Masood N, Malik FA, Kayani MA. Unusual intronic variant in GSTP1 in head and neck cancer in Pakistan. Asian Pacific Journal of Cancer Prevention. 2012; 13(4), 1683–1686.
Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants Differential effects on localization, RB phosphorylation, and cellular transformation. Journal of Biological Chemistry. 2003; 278(32), 30339–30347.
Comstock CE, Augello MA, Benito RP, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clinical Cancer Research. 2009; 15(17), 5338–5349.
Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome Medicine. 2015; 7(1), 45.
Erdem M, Ozgul I, Dioken DN, et al. Identification of an mRNA isoform switch for HNRNPA1 in breast cancers. Scientific Reports. 2021; 11, 24444. https://doi.org/10.1038/s41598-021-04007-y.
Cloutier P, Toutant J, Shkreta L, et al. Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. Journal of Biological Chemistry. 2008; 283, 21315–21324.
Stevens M, Oltean S. Modulation of the apoptosis gene Bcl-x function through alternative splicing. Frontiers Genetics. 2019; 10, 804.
Gacita AM, Dellefave-Castillo L, Page PGT, et al. Altered Enhancer and Promoter Usage Leads to Differential Gene Expression in the Normal and Failed Human Heart. Circulation:HeartFailure.2020;13,e006926.Doi:10.1161/CIRCHEARTFAILURE.120.006926.
Heinig M, Adriaens ME, Schafer S, et al. Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy. Genome Biology. 2017; 18, 170. Doi:10.1186/s13059-017-1286-z.
Kim TH, Barrera LO, Zheng M, et al. A high-resolution map of active promoters in the human genome. Nature. 2005; 436, 876–880. Doi: 10.1038/nature03877.
Cooper SJ, Trinklein ND, Anton ED, et al. Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. Genome Research. 2006; 16, 1–10. Doi: 10.1101/gr.4222606.
Oliveira SM, Zhang YH, Solis RS, et al. AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circulation Research. 2012; 110, 1192–1201. Doi: 10.1161/CIRCRESAHA.111.259952.
Zhu C, Wu J, Sun H, et al. Single-molecule, full-length transcript isoform sequencing reveals disease-associated RNA isoforms in cardiomyocytes. Nature Communications. 2021; 12, 4203. https://doi.org/10.1038/s41467-021-24484-z.
Lightbody AA, Reiss AL. Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies. Developmental Disabilities Research Reviews. 2009; 15, 343–352.
Nobile V, Pucci C, Chiurazzi P. DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome. Biomolecules. 2021, 11, 296. https://doi.org/10.3390/biom11020296.
De Rubeis S, Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability. Molecular and Cellular Neuroscience. 2010; 43, 43–50.
Zukin RS, Richter JD, Bagni C. Signals, synapses, and synthesis: how new proteins control plasticity. Frontiers Neural Circuits. 2009; 3, 14.
Tassone F, De Rubeis S, Carosi C, et al. Differential usage of transcriptional start sites and polyadenylation sites in FMR1 premutation alleles. Nucleic Acids Research. 2011; 39(14), 6172-6185. Doi:10.1093/nar/gkr100.
Zafarullah M , Tang HT , Durbin Johnson B, et al. FMR1 locus isoforms: potential biomarker candidates in fragile X associated tremor/ataxia syndrome (FXTAS). Scientific Reports. 2020; 10, 11099. https://doi.org/10.1038/s41598-020-67946-y.
Curinha A, Oliveira Braz S, Pereira-Castro I, et al. Implications of polyadenylation in health and disease. Nucleus. 2014; 5, 508–519.
Chang JW, Yeh HS, Yong J. Alternative polyadenylation in human diseases. Endocrinology and Metabolism. 2017; 32, 413–421.
Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics. 2011; 43, 1098–1103.
Hellquist A, Zucchelli M, Kivinen K, et al. The human GIMAP5 gene has a common polyadenylation polymorphism increasing risk to systemic lupus erythematosus. Journal of Medical Genetics. 2007; 44, 314–321.
Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000; 95, 1517–1532.
Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and riskof myocardial infarction, stroke, and venousthrombosis in a large cohort of US men. Circulation. 1999; 99, 999–1004.
Sheets MD, Ogg SC, Wickens MP. Point mutations in AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. Nucleic Acids Research. 1990; 18, 5799–5805.
Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3ʹend formation: a new genetic mechanism contributingto hereditary thrombophilia. Nature Genetics. 2001; 28, 389–392.
Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in theprothrombin gene; effect on protein levels and 3ʹ-endformation. Journal of Thrombosis and Haemostasis. 2004; 2, 119–127.
Singh P, Alley TL, Wright SM, et al. Global changes in processing of mRNA 3ʹ untranslated regions characterize clinically distinct cancer subtypes. Cancer Research. 2009; 69, 9422–9430.
Gruber AJ, Schmidt R, Ghosh S, et al. Discovery of physiological and cancer-related regulators of 3ʹ UTR processing with KAPAC. Genome Biology. 2018; 19, 44.
Xue Z, Warren RL, Gibb EA, et al. Recurrent tumor-specific regulation of alternative polyadenylation of cancer-related genes. BMC Genomics. 2018; 19, 536.
Lee SH, Singh I, Tisdale S, et al. Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature. 2018; 561, 127–131.
Green LM, Labue M, Lazarus JP, et al. Reduced cell-cell communication in experimentally induced autoimmune thyroid disease. Endocrinology. 1996, 137(7), 2823–2832.
Oh S, Ri Y, Bennett MV, et al., Changes in permeability caused by connexin 32 mutations underlie X-linked Charcot-Marie-Tooth disease. Neuron. 1997; 19(4), 927–938.
Smyth JW, Shaw RM. Autoregulation of connexin43 gap junction formation by internally translated isoforms. Cell Reports. 2013; 5(3), 611–618.
Salat-Canela C, Sese M, Peula C, et al., Internal translation of the connexin 43 transcript. Cell Communication and Signaling. 2014; 12(1), 31.
James CC, Smyth JW. Alternative mechanisms of translation initiation: an emerging dynamic regulator of the proteome in health and disease. Life Science. 2018; 212, 138–144. Doi:10.1016/j.lfs.2018.09.054.
Lakhdari O, McAllister CS, Wang M, et al. TLR3 signaling is downregulated by a MAVS isoform in epithelial cells. Cellular Immunology. 2016; 310, 205–210.
Marshall HD, Urban SL, Welsh RM. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. Journal of Virology. 2011; 85(12), 5929–5939.
Elliott CE, Becker B, Oehler S, et al. Plectin transcript diversity: identification and tissue distribution of variants with distinct first coding exons and rodless isoforms. Genomics. 1997; 42, 115–125.
Zhang T, Haws P, Wu Q. Multiple variable first exons: a mechanism for cell-and tissue-specific gene regulation. Genome Research. 2004; 14, 79-89.
Andrä K, Lassmann H, Bittner R, et al. Targeted inactivation of plectin reveals essential function in maintaining the integrity of skin, muscle and heart cytoarchitecture. Genes & Development. 1997; 11, 3143-3156.
Andrä K, Kornacker I, Jorgl A, et al. Plectin isoform specific rescue of the hemidesmosomal defects in plectin (-/-) keratinocytes. Journal of Investigative Dermatology. 2003; 120, 189-197.
Rezniczek GA, Konieczny P, Nikolic B, et al. Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with β-dystroglycan. Journal of Cell Biology. 2007; 176, 965-977.
Fuchs P, Zörer M, Reipert S, et al. Targeted Inactivation of a Developmentally Regulated Neural Plectin Isoform (Plectin 1c) in Mice Leads to Reduced Motor Nerve Conduction Velocity. The Journal of Biological Chemistry. 2009; 284 (39), 26502–26509.
Uitto J, Pulkkinen L, Smith FJD, et al. Plectin and human genetic disorders of the skin and muscle. The paradigm of epidermolysis bullosa with muscular dystrophy. Experimental Dermatology. 1996; 5, 237–246.
Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. Journal of Investigative Dermatology. 2005; 124, 111–115.
Nakamura H, Sawamura D, Goto M, et al. Epidermolysis bullosa simplex associated with pyloric atresia is a novel clinical subtype caused by mutations in the plectin gene (PLEC1). Journal of Molecular Diagnostics. 2005; 7, 28–35.
Koss-Harnes D, Jahnsen FL,Wiche G, et al. Plectin abnormality in epidermolysis bullosa simplex Ogna: non-responsiveness of basal keratinocytes to some anti-rat plectin antibodies. Experimental Dermatology. 1997; 6, 41–48.
Gundesli H, Talim B, Korkusuz P, et al. Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal recessive limb-girdle muscular dystrophy. American Journal of Human Genetics. 2010; 87(6), 834-841.
Mroczek M, Durmus H, Töpf A, et al. Four Individuals with a Homozygous Mutation in Exon 1f of the PLEC Gene and Associated Myasthenic Features. Genes. 2020; 11, 716.
Deev RV, Bardakov SN, Mavlikeev MO, et al. Glu20Ter Variant in PLEC 1f Isoform Causes Limb-Girdle Muscle Dystrophy with Lung Injury. Frontiers in Neurology. 2017; 8, 367. Doi: 10.3389/fneur.2017.00367.
Gostyńska KB, Nijenhuis M, Lemmink H, et al. Mutation in exon 1a of PLEC, leading to disruption of plectin isoform 1a, causes autosomal-recessive skin-only epidermolysis bullosa simplex. Human Molecular Genetics. 2015; 24 (11), 3155–3162. Doi: 10.1093/hmg/ddv066.
